ArticleMicrobiome2026
Invertebrates gut viromes mediate microbial adaptation to pharmaceutical diversity under warming.
Article in Microbiome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmaceutical pollution is an emerging environmental concern that can disrupt microbial communities and ecological processes, while climate warming adds further stress with broad ecological consequences. Soil invertebrates such as collembolans harbor gut microbiomes essential for host health and ecosystem stability, yet the responses of these communities-particularly viral communities-to combined pharmaceutical and warming pressures remain unclear. Here, we used controlled microcosm experiments with Folsomia candida to investigate how pharmaceutical diversity and fluctuating warming jointly shape gut microbiomes through bacteria-virus interactions.
resultsPharmaceutical diversity significantly reduced the alpha diversity of gut viral communities in F. candida, an effect not observed in surrounding soils. Diurnal warming increased the proportion of lysogenic phages and enhanced auxiliary metabolic genes (AMGs) such as ACADM and nrdA. Functional validation in Escherichia coli BL21 confirmed that these genes mitigate oxidative stress and improve host thermal tolerance. In contrast, diverse pharmaceuticals increased the proportion of lytic phages, likely driving nutrient turnover through a "kill-the-winner" dynamic that stimulated bacterial taxa involved in pharmaceutical degradation. Moreover, warming amplified the disruption of gut bacterial communities caused by pharmaceutical diversity and strengthened bacteria-virus co-occurrence networks.
conclusionsOur findings reveal that gut viruses act as pivotal regulators of microbial adaptation under concurrent chemical and climate stressors. By mediating host resilience and microbial dynamics, the gut virome provides mechanistic insights into ecosystem stability, and may also serve as an early indicator of combined pharmaceutical and warming stress in soil invertebrate systems, underscoring the need to integrate viral-microbial interactions into One Health framework for environmental risk assessment. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.